Istar

Sixth Street Expands Real Estate Platform, Adding Marcos Alvarado as Partner

Retrieved on: 
Tuesday, January 16, 2024

Sixth Street, a leading global investment firm with over $75 billion in assets under management, today announced the expansion of its Sixth Street Real Estate platform with the addition of Marcos Alvarado as a Partner of the firm and Head of U.S. Real Estate.

Key Points: 
  • Sixth Street, a leading global investment firm with over $75 billion in assets under management, today announced the expansion of its Sixth Street Real Estate platform with the addition of Marcos Alvarado as a Partner of the firm and Head of U.S. Real Estate.
  • Sixth Street Real Estate is a global investment platform focused on acquiring properties and providing financing solutions across the full range of real estate sectors, including residential, hospitality, office, industrial, and retail.
  • “Sixth Street is one of the few platforms with the scale, experience, and flexible approach to be a significant force in the future of the global real estate market,” said Alvarado.
  • “I am thrilled to join this highly experienced team and work alongside them to help develop creative solutions for real estate asset owners, while expanding the depth and breadth of our real estate business.”

iSTAR Medical Expands International Commercial Rollout of MINIject® with Successful First Implants Completed in Australia

Retrieved on: 
Wednesday, January 10, 2024

Australia is the first territory outside of Europe for iSTAR Medical to have progressed its commercial roll out of MINIject®, following the successful expansion into countries including Germany, the UK, Switzerland, and most recently, Ireland.

Key Points: 
  • Australia is the first territory outside of Europe for iSTAR Medical to have progressed its commercial roll out of MINIject®, following the successful expansion into countries including Germany, the UK, Switzerland, and most recently, Ireland.
  • With this expansion, glaucoma patients across Australia will now be able to benefit from MINIject®, the only commercially available supraciliary MIGS implant.
  • MINIject® has demonstrated meaningful and sustained performance, combined with a favorable safety profile, and offers a treatment option for open-angle glaucoma.
  • I would like to thank the clinicians involved for helping us achieve this significant milestone and look forward to reaching more patients throughout Australia and beyond.”

iSTAR Medical continues European expansion with first MINIject® surgeries in the Netherlands

Retrieved on: 
Friday, December 22, 2023

Glaucoma is the cause of visual impairment or blindness in four percent of the total number of patients in the Netherlands1.

Key Points: 
  • Glaucoma is the cause of visual impairment or blindness in four percent of the total number of patients in the Netherlands1.
  • Patients were successfully implanted at the University Eye Clinic of the Maastricht University Medical Center+ by Prof. Henny Beckers, Head of the Glaucoma Clinic and Director of the Ophthalmology Residency Program.
  • iSTAR Medical’s rollout of MINIject® in the Netherlands adds to its existing portfolio of European countries.
  • MINIject® continues to demonstrate meaningful and sustained performance in lowering intraocular pressure (IOP) combined with a favorable safety profile.

Bill Stein Joins Crusoe Board of Advisors

Retrieved on: 
Thursday, November 30, 2023

Crusoe Energy Systems LLC (“Crusoe”) announced today that A. William “Bill” Stein, former CEO of Digital Realty Trust, has joined the company’s Board of Advisors.

Key Points: 
  • Crusoe Energy Systems LLC (“Crusoe”) announced today that A. William “Bill” Stein, former CEO of Digital Realty Trust, has joined the company’s Board of Advisors.
  • Stein joins Crusoe on the heels of the recent announcement of a significant expansion of its high performance cloud computing business with new capacity and additional financing earmarked for further GPU purchases and data center expansion.
  • “This is a critical moment for Crusoe as they expand their digital infrastructure offerings,” said Stein.
  • Both Dolan and McGrath had previously served as members of Crusoe’s Board of Advisors for multiple years.

iSTAR Medical conducts first MINIject® surgeries in Ireland, expanding commercial rollout in Europe

Retrieved on: 
Tuesday, October 31, 2023

iSTAR Medical conducts first MINIject® surgeries in Ireland, expanding commercial rollout in Europe

Key Points: 
  • iSTAR Medical conducts first MINIject® surgeries in Ireland, expanding commercial rollout in Europe
    WAVRE, Belgium — 31 October 2023: iSTAR Medical , a medtech company delivering breakthrough eye care solutions to patients, today announces that the first patients in Ireland have been implanted with MINIject ®, expanding the commercial rollout of the Company’s minimally-invasive glaucoma surgery (MIGS) device across Europe.
  • Currently the only commercially available supraciliary MIGS implant, MINIject® has demonstrated meaningful and sustained performance, combined with a favorable safety profile.
  • The continuation of our commercial rollout of MINIject® with the recent implantations in Ireland represents iSTAR Medical’s mission to preserve the vision of glaucoma patients around the world.
  • As we continue with our global expansion, we look forward to making MINIject® more widely available to patients.”

iSTAR Medical presents positive three-year results for MINIject® from STAR-GLOBAL trial

Retrieved on: 
Thursday, September 7, 2023

WAVRE, Belgium — 7 September 2023: iSTAR Medical , a medtech company delivering breakthrough eye care solutions to patients, today announces positive three-year data from the STAR-GLOBAL trial for MINIject®.

Key Points: 
  • WAVRE, Belgium — 7 September 2023: iSTAR Medical , a medtech company delivering breakthrough eye care solutions to patients, today announces positive three-year data from the STAR-GLOBAL trial for MINIject®.
  • The data was presented at the iSTAR Medical symposium which took place in June at the World Glaucoma Congress (WGC) in Rome, Italy.
  • STAR-GLOBAL is an extension trial investigating the long-term safety and efficacy of patients up to five-years of follow-up.
  • Patients implanted with the MINIject® supraciliary MIGS device are invited to enroll into STAR-GLOBAL upon completion at two years of an iSTAR Medical trial, to continue follow-up from two to five years.

KREST Names Julia Butler As Chief Investment Officer

Retrieved on: 
Wednesday, May 24, 2023

KKR, a leading global investment firm, today announced that the Board of Directors of KKR Real Estate Select Trust Inc. (“KREST” or the “Fund”) has appointed Julia Butler to the newly created role of Chief Investment Officer (“CIO”) of KREST.

Key Points: 
  • KKR, a leading global investment firm, today announced that the Board of Directors of KKR Real Estate Select Trust Inc. (“KREST” or the “Fund”) has appointed Julia Butler to the newly created role of Chief Investment Officer (“CIO”) of KREST.
  • A veteran real estate investor and Managing Director at KKR, Ms. Butler is now on KREST’s dedicated senior leadership team.
  • “We have built KREST to provide individual investors access to the full breadth of KKR’s global real estate platform with a dynamic investment strategy designed to deliver attractive yield and long-term performance across different macroeconomic environments,” said Ralph Rosenberg, Chairman of KREST and Global Head of KKR Real Estate.
  • Billy Butcher, Chief Executive Officer of KREST and Chief Operating Officer of KKR Global Real Estate, said: “We believe we are entering a once-a-decade real estate investing environment with the debt capital markets pullback creating potential attractive new investment opportunities for KREST.

Michelle MacKay Named Next Cushman & Wakefield CEO; John Forrester to Retire From the Company

Retrieved on: 
Thursday, May 4, 2023

As part of the Company’s long-standing succession plan, Cushman & Wakefield’s Board of Directors appointed Michelle MacKay, currently President and Chief Operating Officer (COO), to assume the role of CEO as of July 1, 2023.

Key Points: 
  • As part of the Company’s long-standing succession plan, Cushman & Wakefield’s Board of Directors appointed Michelle MacKay, currently President and Chief Operating Officer (COO), to assume the role of CEO as of July 1, 2023.
  • In addition, Ms. MacKay was elected to serve on the Board of Directors, effective July 1, 2023.
  • “I am proud of our great company and what our Cushman & Wakefield colleagues around the world have accomplished.
  • Mr. McDonald has been with Cushman & Wakefield for more than 20 years, most recently serving as President of Cushman & Wakefield since 2021, leading the firm’s largest business lines in the Americas and Asia Pacific regions.

Lazard Ltd Reports First-Quarter 2023 Results

Retrieved on: 
Friday, April 28, 2023

For a list of publicly announced Financial Advisory transactions on which Lazard advised in the first quarter of 2023, or continued to advise or completed since March 31, 2023, please visit our website at www.lazard.com/financial-advisory/transactions/ .

Key Points: 
  • For a list of publicly announced Financial Advisory transactions on which Lazard advised in the first quarter of 2023, or continued to advise or completed since March 31, 2023, please visit our website at www.lazard.com/financial-advisory/transactions/ .
  • On April 26, 2023, Lazard declared a quarterly dividend of $0.50 per share on its outstanding common stock.
  • We believe that presenting our results on an adjusted basis, in addition to the U.S. GAAP results, is the most meaningful and useful way to compare our operating results across periods.
  • ET on April 28, 2023, to discuss the company’s financial results for the first quarter of 2023.

iSTAR Medical initiates international STAR-VI trial for the use of MINIject in conjunction with cataract surgery

Retrieved on: 
Wednesday, March 15, 2023

iSTAR Medical’s STAR-VI trial is a prospective, interventional, multi-center, single-arm study which seeks to implant a total of 30 patients at up to seven sites in Europe and in Central America.

Key Points: 
  • iSTAR Medical’s STAR-VI trial is a prospective, interventional, multi-center, single-arm study which seeks to implant a total of 30 patients at up to seven sites in Europe and in Central America.
  • Patients will be followed for two years after their cataract surgery and concurrent MINIject® implantation.
  • MINIject® is iSTAR Medical’s minimally-invasive glaucoma surgery (MIGS) device and is currently the only commercially available supraciliary MIGS implant.
  • We are committed to delivering our breakthrough eye care solutions to patients globally and look forward to reporting clinical data from this study in due course.”